TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Brief Summary: Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of omega-3 fatty acids, this study aims to evaluate treatment effects of concentrated omega-3 fatty acids (Triomar™) in MS, both as monotherapy and in combination with standard immunomodulatory therapy defined as interferon-beta 1a (Rebif™).


Options:
A: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo
B: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
C: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
D: Intervention Type: DRUG; Name: Epanova™ (Omega-3 Free Fatty Acids); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Brief Summary: Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of omega-3 fatty acids, this study aims to evaluate treatment effects of concentrated omega-3 fatty acids (Triomar™) in MS, both as monotherapy and in combination with standard immunomodulatory therapy defined as interferon-beta 1a (Rebif™).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsule | Arm Label: EPA-E 1800 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Arm Label: EPA-E 2700 mg/day; Type: EXPERIMENTAL; Interventions: Drug: EPA-E 300 mg capsule | Intervention Type: DRUG; Name: Placebo capsule; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 1800 mg/day | Intervention Type: DRUG; Name: EPA-E 300 mg capsule; Assigned to Arm(s): EPA-E 2700 mg/day
B: Intervention Type: PROCEDURE; Name: Supplementation with fish oil versus placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
D: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Brief Summary: Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of omega-3 fatty acids, this study aims to evaluate treatment effects of concentrated omega-3 fatty acids (Triomar™) in MS, both as monotherapy and in combination with standard immunomodulatory therapy defined as interferon-beta 1a (Rebif™).


Options:
A: Arm Label: Fish oil concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fish oil concentrate | Arm Label: Placebo oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fish oil concentrate; Assigned to Arm(s): Fish oil concentrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo oil
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
D: Arm Label: MD1003; Type: EXPERIMENTAL; Interventions: Drug: MD1003 100mg capsule | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: MD1003 100mg capsule | Intervention Type: DRUG; Name: MD1003 100mg capsule; Assigned to Arm(s): MD1003, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Brief Summary: Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of omega-3 fatty acids, this study aims to evaluate treatment effects of concentrated omega-3 fatty acids (Triomar™) in MS, both as monotherapy and in combination with standard immunomodulatory therapy defined as interferon-beta 1a (Rebif™).


Options:
A: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Flaxseed; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Flaxseed; Assigned to Arm(s): Flaxseed | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Triomar™ (omega-3 fatty acids); Assigned to Arm(s): N/A
D: Arm Label: Fish oil; Type: EXPERIMENTAL; Interventions: Drug: Fish oil | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Fish oil; Assigned to Arm(s): Fish oil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ultrafiltration for the Chronic Treatment of Severe Congestive Heart Failure
Brief Summary: Patients with severe congestive heart failure show increased fluid body content which is often resistant to conventional diuretic therapy. Therefore, chronic heart failure patients have frequent access to the emergency room and hospital for hemodynamic instability. Ultrafiltration is a simple renal replacement therapy which reduces fluid overload. The purpose of this study is to determine whether periodic ultrafiltration sessions maintain patients in stable clinical condition and reduce hospitalisations as well as access to emergency heart failure treatment.


Options:
A: Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Drug: loop diuretic | Arm Label: Usual care plus tolvaptan; Type: ACTIVE_COMPARATOR; Interventions: Drug: loop diuretic, Drug: tolvaptan | Arm Label: ultrafiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ultrafiltration | Intervention Type: DRUG; Name: loop diuretic; Assigned to Arm(s): Usual care plus tolvaptan, usual care | Intervention Type: DRUG; Name: tolvaptan; Assigned to Arm(s): Usual care plus tolvaptan | Intervention Type: PROCEDURE; Name: ultrafiltration; Assigned to Arm(s): ultrafiltration
B: Arm Label: Ultrafiltration Group; Type: ACTIVE_COMPARATOR; Interventions: Device: CHIARA-System | Arm Label: Control group (Usual care IV diuretics); Type: OTHER; Interventions: Other: Usual care IV diuretics | Intervention Type: DEVICE; Name: CHIARA-System; Assigned to Arm(s): Ultrafiltration Group | Intervention Type: OTHER; Name: Usual care IV diuretics; Assigned to Arm(s): Control group (Usual care IV diuretics)
C: Intervention Type: DEVICE; Name: Aquadex system; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: IV diuretic; Assigned to Arm(s): N/A
D: Arm Label: Ultrafiltration; Type: EXPERIMENTAL; Interventions: Procedure: ultrafiltration | Arm Label: Usual treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ultrafiltration | Intervention Type: PROCEDURE; Name: ultrafiltration; Assigned to Arm(s): Ultrafiltration, Usual treatment

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus
Brief Summary: This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control in patients with type 2 diabetes by making their own insulin work more efficiently.


Options:
A: Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A
B: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
C: Arm Label: Diabetic Participants: Metformin HCl+Placebo for Colesevelam; Type: PLACEBO_COMPARATOR; Interventions: Drug: Metformin HCl and Colesevelam Placebo | Arm Label: Diabetic participants: Metformin HCl + Colesevelam; Type: EXPERIMENTAL; Interventions: Drug: Metformin HCl tablets and Colesevelam tablets | Arm Label: Pre-diabetic Participants: Colesevelam Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Colesevelam placebo | Arm Label: Pre-diabetes Participants: Colesevelam; Type: EXPERIMENTAL; Interventions: Drug: Colesevelam | Intervention Type: DRUG; Name: Metformin HCl and Colesevelam Placebo; Assigned to Arm(s): Diabetic Participants: Metformin HCl+Placebo for Colesevelam | Intervention Type: DRUG; Name: Metformin HCl tablets and Colesevelam tablets; Assigned to Arm(s): Diabetic participants: Metformin HCl + Colesevelam | Intervention Type: DRUG; Name: Colesevelam placebo; Assigned to Arm(s): Pre-diabetic Participants: Colesevelam Placebo | Intervention Type: DRUG; Name: Colesevelam; Assigned to Arm(s): Pre-diabetes Participants: Colesevelam
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Colesevelam hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Brief Summary: The purpose of this study is to assess the clinical effectiveness and safety of golimumab intravenous (IV) infusions every 12 weeks with or without Methotrexate (MTX), compared with MTX alone, in patients with active rheumatoid arthritis (RA) despite concurrent MTX treatment. In addition, the safety of subcutaneous (SC) golimumab injections following transition from IV golimumab infusions will also be evaluated.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Tocilizumab 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Placebo to adalimumab | Arm Label: Adalimumab 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab, Drug: Placebo to tocilizumab | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to tocilizumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to adalimumab; Assigned to Arm(s): Tocilizumab 8 mg/kg
D: Arm Label: Group I: 2mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group II: 2mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group III: 4mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group IV: 4mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group V: IV Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group II: 2mg/kg Golimumab only, Group III: 4mg/kg Golimumab + MTX, Group IV: 4mg/kg Golimumab only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group III: 4mg/kg Golimumab + MTX, Group V: IV Placebo + MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group II: 2mg/kg Golimumab only, Group IV: 4mg/kg Golimumab only, Group V: IV Placebo + MTX

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acoustic Assessment of Nebulized Epinephrine Versus Albuterol for RSV Bronchiolitis- a Double Blind Study
Brief Summary: Bronchiolitis is a common disease of infancy and a main reason for infants' hospital admissions in the first 2 years of life. The main cause of bronchiolitis is RSV (respiratory syncytial virus). Though, Treatment is mainly supportive, the treatment benefit of nebulized epinephrine or albuterol has been largely debated for the past years. Most of the clinical studies used clinical parameters to detect and compare the effectiveness of such medical interventions. In this study we will use non invasive computerized method of wheeze and crackles quantification to compare the effectiveness of nebulized epinephrine vs albuterol in RSV Bronchiolitis.


Options:
A: Arm Label: Nebulized 3% Saline; Type: EXPERIMENTAL; Interventions: Drug: Nebulized 3% saline | Arm Label: Nebulized 0.9% Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nebulized 0.9% Normal Saline | Intervention Type: DRUG; Name: Nebulized 3% saline; Assigned to Arm(s): Nebulized 3% Saline | Intervention Type: DRUG; Name: Nebulized 0.9% Normal Saline; Assigned to Arm(s): Nebulized 0.9% Normal Saline
B: Intervention Type: DRUG; Name: nebulized epinephrine and nebulized albuterol; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Epinephrine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: albuterol (salbutamol); Assigned to Arm(s): N/A
D: Arm Label: heliox; Type: OTHER; Interventions: Drug: heliox | Arm Label: oxygen; Type: OTHER; Interventions: Drug: oxygen | Intervention Type: DRUG; Name: heliox; Assigned to Arm(s): heliox | Intervention Type: DRUG; Name: oxygen; Assigned to Arm(s): oxygen

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the 'Mother and Baby' Program on New Mothers' Psychological and Physical Well-Being.
Brief Summary: The study investigates the effect of the 'Mother and Baby' (M\&B) program on the psychological health and well-being of new mothers 6-10 weeks following the birth of their baby. The M\&B program is an 8-week program of group exercise and education sessions provided by various health professionals. The design of the study is a comprehensive cohort design, including a randomised controlled trial. The primary outcome measure is the Affect Balance Scale. The hypotheses are:

1. The M\&B program has a positive effect on new mothers' psychological health and well-being.
2. The M\&B program increases participation in regular physical activity.
3. the M\&B program benefits first time mothers more than women who have had more than one child.


Options:
A: Arm Label: Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Diet | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Diet and Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Diet and Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): Diet | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Diet and Exercise; Assigned to Arm(s): Diet and Exercise
B: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Exercise and education; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): 2
D: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: moderate exercise and healthy, low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate exercise and healthy, low-fat diet; Assigned to Arm(s): Lifestyle counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A One-Year, Randomized, Open-Label, Parallel-Arm, Phase 3 Long-Term Safety Trial, With Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects With Chronic Pain
Brief Summary: The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back pain, or pain caused by knee or hip osteoarthritis.


Options:
A: Arm Label: Tapentadol Prolonged Release; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol Prolonged Release | Intervention Type: DRUG; Name: Tapentadol Prolonged Release; Assigned to Arm(s): Tapentadol Prolonged Release
B: Arm Label: Tapentadol (CG5503); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol (CG5503) ER | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): Oxycodone | Intervention Type: DRUG; Name: Tapentadol (CG5503) ER; Assigned to Arm(s): Tapentadol (CG5503)
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: CG5503; Type: EXPERIMENTAL; Interventions: Drug: CG5503 | Intervention Type: DRUG; Name: CG5503; Assigned to Arm(s): CG5503 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Matching Placebo (twice daily); Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo (twice daily) | Arm Label: Tapentadol ER (100 to 250 mg twice daily); Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (100 to 250 mg twice daily) | Arm Label: Oxycodone CR (20 to 50 mg twice daily); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR (20 to 50 mg twice daily) | Intervention Type: DRUG; Name: Tapentadol ER (100 to 250 mg twice daily); Assigned to Arm(s): Tapentadol ER (100 to 250 mg twice daily) | Intervention Type: DRUG; Name: Matching Placebo (twice daily); Assigned to Arm(s): Matching Placebo (twice daily) | Intervention Type: DRUG; Name: Oxycodone CR (20 to 50 mg twice daily); Assigned to Arm(s): Oxycodone CR (20 to 50 mg twice daily)

Answer: B